Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 11,419 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD0120, SOC; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 8 more

Conditions: Biliary Cancer
Interventions: SPI-1620, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 3 more

Conditions: Chronic Post Traumatic Headache
Interventions: OnabotulinumtoxinA; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 18
States / cities: Birmingham, Alabama • San Francisco, California • San Jose, California + 11 more

Conditions: Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 397
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more

Conditions: PTSD
Interventions: DESTRESS-WV, Phone Monitoring; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: GARDASIL Vaccination
Interventions: Computer reminder system; Behavioral
Lead sponsor: Planned Parenthood Federation of America; Other
Eligibility: 19 Years to 26 Years · Female only
Enrollment: 365 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Glendale, Arizona • Arvada, Colorado • Denver, Colorado + 6 more

Conditions: Major Depressive Disorder
Interventions: CX157 (TriRima), Placebo; Drug
Lead sponsor: CeNeRx BioPharma Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Birmingham, Alabama • Beverly Hills, California • Washington D.C., District of Columbia + 11 more

Conditions: Migraine Disorders
Interventions: ALD403, Placebo; Biological
Lead sponsor: Alder Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 82
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Macular Telangiectasia Type 2
Interventions: Serine, Fenofibrate; Dietary Supplement · Drug
Lead sponsor: The Lowy Medical Research Institute Limited; Other
Eligibility: 21 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 5 more

Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions: NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab; Drug
Lead sponsor: NuCana plc; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Contraception, Women at Risk for Pregnancy
Interventions: LevoCept; Drug
Lead sponsor: Sebela Women's Health Inc.; Industry
Eligibility: Up to 45 Years · Female only
Enrollment: 1,525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 27
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 20 more

Conditions: Kidney Transplantation
Interventions: Mycophenolate mofetil, Cyclosporine, Tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more

Conditions: Gastrointestinal Diseases
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Autoimmune
Interventions: DiaPep277; Drug
Lead sponsor: DeveloGen Israel, Ltd.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Lexington, Kentucky + 4 more

Conditions: Posttraumatic Stress Disorder
Interventions: Enhanced Implementation Strategy, Standard Implementation Strategy; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Diego, California • Denver, Colorado + 3 more

Conditions: Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions: dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 21 more

Conditions: Adrenocortical Carcinoma
Interventions: suramin, therapeutic hydrocortisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 65
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Interventions: Cabozantinib S-malate, Pembrolizumab; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Trauma, Psychological, Trauma and Stressor Related Disorders
Interventions: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT), School-Adapted TF-CBT (S-TF); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 7 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ADHD, Autism
Interventions: Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 5 Years to 16 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: oxaliplatin; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1, TBC-3B Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more

Search by objective public record fields.

A Study of AZD0120 in Autoimmune Diseases

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA

Evaluation of Patients Who Have Not Had Success With Zidovudine

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Evaluation of Web-Based CBT for Women Veterans With PTSD

Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series

A Study of CX157 (TriRima) for the Treatment of Depression

A Multicenter Assessment of ALD403 in Chronic Migraine

IVIG for Infection Prevention After CAR-T-Cell Therapy

Serine and Fenofibrate Study in Patients With MacTel Type 2

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

Regulation of Human Intestinal Bile Acid Transport in Health and Disease

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

TOP Implementation Project

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Systematic Redesign of Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.